{
    "clinical_study": {
        "@rank": "90795", 
        "arm_group": {
            "arm_group_label": "Mesenchymal Stromal Cells", 
            "arm_group_type": "Experimental", 
            "description": "A single intravenous infusion of ex-vivo expanded autologous MSCs will be performed in patients in addition to the living-donor kidney transplantation.\n2x10 elevated to sxth power MSCs per kilogram body weight previously isolated from the same recipient will be infused intravenously the day before the kidney transplant procedure."
        }, 
        "brief_summary": {
            "textblock": "The general aim of the present study is to test a cell therapy with autologous ex-vivo\n      expanded mesenchymal stromal cells (MSCs) as a strategy to induce tolerance in living-donor\n      kidney transplant recipients. MSCs will be prepared accordingly to established protocols,\n      starting from bone marrow explants of living-donor kidney transplant recipients obtained 3-4\n      months before kidney transplant. From these samples, MSCs will be expanded in Good\n      Manufacturing Practice (GMP) approved facilities and used for the present study in patients\n      undergoing kidney transplantation."
        }, 
        "brief_title": "Mesenchymal Stromal Cells in Kidney Transplant Recipients", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Kidney Transplant Rejection", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients;\n\n          -  Aged 18 or older;\n\n          -  Living-donor (related and unrelated, spouse/husband) kidney transplant   recipients;\n\n          -  Non-Human Leukocyte Antigen (HLA) identical with the donor (one or two haplotype\n             mismatches);\n\n          -  First kidney transplant;\n\n          -  Capable of understanding the purpose and risk of the study;\n\n          -  Written informed consent.\n\n        Exclusion Criteria:\n\n          -  MSC donor positive for HIV-1, HIV-2, hepatitis B virus (HBV),hepatitis C virus (HCV),\n             syphilis;\n\n          -  Specific contraindication to MSC infusion;\n\n          -  Any clinical relevant condition that might affect study participation and/or study\n             results;\n\n          -  Pregnant women and nursing mothers;\n\n          -  Unwillingness or inability to follow study protocol in the investigator's opinion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012153", 
            "org_study_id": "MSC-Tx tolerance", 
            "secondary_id": "2013-003221-29"
        }, 
        "intervention": {
            "arm_group_label": "Mesenchymal Stromal Cells", 
            "intervention_name": "Mesenchymal Stromal Cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Mesenchymal stromal cells", 
            "Kidney transplantation", 
            "Tolerance"
        ], 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "contact": {
                "email": "pruggenenti@hpg23.it", 
                "last_name": "Piero Ruggenenti, MD", 
                "phone": "0039 035 2674037"
            }, 
            "facility": {
                "address": {
                    "city": "Bergamo", 
                    "country": "Italy", 
                    "zip": "24127"
                }, 
                "name": "U.O. Nefrologia e Dialisi"
            }, 
            "investigator": {
                "last_name": "Eliana Gotti, MD", 
                "role": "Sub-Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "AUTOLOGOUS MESENCHYMAL STROMAL CELLS TO INDUCE TOLERANCE IN LIVING-DONOR KIDNEY TRANSPLANT RECIPIENTS", 
        "overall_contact": {
            "email": "norberto.perico@marionegri.it", 
            "last_name": "Norberto Perico, MD", 
            "phone": "0039 035 45351"
        }, 
        "overall_official": [
            {
                "affiliation": "A.O. Papa Giovanni XXIII, Bergamo, Italy", 
                "last_name": "Giuseppe Remuzzi, MD", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "IRCCS Istituto di Ricerche Farmacologiche Mario Negri", 
                "last_name": "Norberto Perico, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "A.O. Papa giovanni XXIII, Bergamo, Italy", 
                "last_name": "Giovanni Rota, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "IRCCS Istituto di Ricerche Farmacologiche Mario Negri", 
                "last_name": "Federica Casiraghi", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Laboratorio G. Lanzani, Bergamo, Italy", 
                "last_name": "Martino Introna, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "A.O. Papa Giovanni XXIII, Bergamo, Italy", 
                "last_name": "Alessandro Rambaldi, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Italy: National Institute of Health", 
                "Italy: Italian Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Circulating na\u00efve and memory T cell count (CD45RA/CD45RO) (flow cytometry analysis).", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline at 6 and 12 months after transplant."
            }, 
            {
                "measure": "T-cell function by ELISPOT assay in mixed lymphocyte reaction.", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline at 6 and 12 months after transplant."
            }, 
            {
                "description": "At each visit the overall clinical condition of the patient will be evaluated and any adverse event will be recorded.", 
                "measure": "Number of adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "Changes from baseline up to 48 months."
            }, 
            {
                "measure": "Circulating regulatory T cell count.", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline at 6 and 12 months after transplant."
            }, 
            {
                "measure": "Urinary FOXP3 mRNA expression  evaluated by real time quantitative PCR.", 
                "safety_issue": "No", 
                "time_frame": "Changes from baseline at 6 and 12 months after transplant."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012153"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Mario Negri Institute for Pharmacological Research", 
        "sponsors": {
            "collaborator": {
                "agency": "A.O. Ospedale Papa Giovanni XXIII", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Mario Negri Institute for Pharmacological Research", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}